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Abstract: Prostate carcinoma is one of the most prevalent cancers worldwide. Multiparametric
magnetic resonance imaging (mpMRI) is a non-invasive tool that can improve prostate lesion detection,
classification, and volume quantification. Machine learning (ML), a branch of artificial intelligence,
can rapidly and accurately analyze mpMRI images. ML could provide better standardization and
consistency in identifying prostate lesions and enhance prostate carcinoma management. This review
summarizes ML applications to prostate mpMRI and focuses on prostate organ segmentation, lesion
detection and segmentation, and lesion characterization. A literature search was conducted to find
studies that have applied ML methods to prostate mpMRI. To date, prostate organ segmentation
and volume approximation have been well executed using various ML techniques. Prostate lesion
detection and segmentation are much more challenging tasks for ML and were attempted in several
studies. They largely remain unsolved problems due to data scarcity and the limitations of current
ML algorithms. By contrast, prostate lesion characterization has been successfully completed in
several studies because of better data availability. Overall, ML is well situated to become a tool that
enhances radiologists’ accuracy and speed.
Keywords: prostate carcinoma; prostate mpMRI; machine learning; artificial intelligence; deep
learning; neural network

1. Introduction
Prostate carcinoma (PCa) is the most common cancer and the third leading cause of cancer-related
death among men in the United States [1]. A major challenge for PCa management is the lack
of non-invasive tools that can differentiate aggressive versus non-aggressive cancer types [2].
This limitation can result in overdiagnosis and overtreatment, as evidenced by the fact that only one
death is prevented for every 48 patients treated for PCa [3]. This overdiagnosis and overtreatment
can lead to unnecessary biopsies, surgeries, radiotherapy, chemotherapy, and patient anxiety [2].
Better diagnostic methods could mitigate these unwarranted procedures. To meet this need for more
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effective screening, multiparametric magnetic resonance imaging (mpMRI) could be implemented to
examine the entire prostate.
MpMRI of the prostate has been increasingly used for PCa screening in recent years [4]. MpMRI’s
current utility in screening stems from a high negative predictive value for prostate cancer. However,
the full potential of mpMRI has not yet been achieved [5]. PCa overdiagnosis could be reduced with
an mpMRI analysis that accomplishes better lesion detection, lesion classification (benign versus
malignant), and lesion volume quantification.
Accurate prostate segmentation and volume estimation can provide invaluable information for the
diagnosis and clinical management of benign prostatic hyperplasia (BPH) and PCa. This can improve
BPH treatment, surgical planning, and predictions of PCa prognosis [6–8]. Prostate segmentation is
necessary for magnetic resonance imaging (MRI) transrectal ultrasound (TRUS) fusion biopsy, which
is increasingly used to diagnose PCa. MRI/TRUS fusion biopsy yield depends on accurate prostate
segmentation on magnetic resonance images because the prostate edges form the reference frames for
fusion with the ultrasound data [8]. Therefore, any inaccuracy in tracing prostate boundaries may lead
to biopsy errors [9]. In addition to segmentation, prostate volume estimation is also a useful metric,
especially with regard to BPH treatment, surgical planning, and PCa prognosis. BPH is one of the
most common diseases that affects elderly men and reaches a prevalence of 90% by the ninth decade of
life [10]. Large prostate volumes in men with BPH indicate a higher likelihood of more severe lower
urinary tract symptoms and urinary retention [11–13]. Furthermore, studies have shown that patients
have differential responses to BPH-targeted medications, depending on prostate size [11]. Additionally,
prostate volume is considered when determining a surgical approach, with each procedure having its
own risk profile [14]. In addition to guiding BPH treatment, prostate volume is used in PCa prognosis.
Prostate size alone is a valuable marker for PCa prognosis; PCa is more accurately detected in prostates
under 50 cm3 than in those over 50 cm3 [6]. Prostate volume is also used to calculate prostate-specific
antigen density, a figure that helps to differentiate BPH from PCa and can also be used to predict
radical prostatectomy outcomes [15–17].
Accuracy of prostate lesion detection, segmentation, and volume estimation is important at
different stages of PCa management. Lesion detection identifies regions for biopsy. Accurate
segmentation is crucial for improved fusion biopsy yields. Additionally, segmentation improves
radiotherapy delivery. Volume estimation predicts prognosis after prostatectomy [18–20]. Prostate
lesion detection is crucial because the effective treatment of PCa directly depends on identifying cancer
at its earliest stage [21–23]. Even though PCa most often follows an indolent course, it can show
rapid progression in some cases. In these instances, lesion recognition on mpMRI is critical because it
provides a region of high suspicion and a higher yield from targeted biopsy [24]. Without mpMRI
lesion detection, random 12 core TRUS biopsies are performed, which may miss small or anteriorly
located PCa [25].
While early prostate lesion detection improves timely PCa treatment, accurate lesion segmentation
can improve radiotherapy [26]. Prostate lesion contouring is a major source of error when administering
radiation therapy. This inexact segmentation can lead to the underdosage of the tumor as well as the
overdosage of normal cells [20]. Although radiotherapy is an effective cancer treatment, its use is
hampered by imprecise delineation. More precise contouring of a malignant lesion can improve lesion
targeting and relative radiotherapeutic dosage, which can lead to lower recurrence rates [26,27].
Pre-operative prostate lesion volume estimation is a key metric for predicting the likelihood of
positive surgical margins, biochemical prostate-specific antigen (PSA) recurrence, and cancer-specific
survival post-prostatectomy [28–31]. This volume is a better indicator of surgical margins than other
factors such as Gleason score and extracapsular extension [28]. Lesion volume also functions as
an independent variable for PSA recurrence, an early sign of recurrent disease which may require
salvage radiation therapy [32]. In addition, lesion volume predicts cancer-specific survival more
accurately than variables such as lymphadenopathy, seminal vesical invasion, and Gleason score [29].
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After prostate lesions have been detected on mpMRI, lesion characterization is important for
selecting appropriate management options. Accurate prostate lesion classification on mpMRI could
preclude biopsies in men with low-grade tumors, reduce the number of biopsy cores, and decrease
the rate of overdiagnosis and false-negative biopsies [33]. Reduction in unnecessary biopsies is
important, as potential TRUS biopsy complications include hematuria, lower urinary tract symptoms,
and temporary erectile dysfunction [34]. Additionally, the number of biopsy cores obtained correlates
with increased risk of complications, including rectal bleeding, hematospermia, bleeding complications,
and acute urinary retention [34]. Furthermore, the overdetection of PCa exerts a major psychological
toll on quality of life and increases the risk of overtreatment [2]. Overtreatment side effects that may
occur after radical prostatectomy and radiotherapy include urinary incontinence, rectal bleeding and
fistulae, and erectile dysfunction [2,35–37].
Artificial intelligence (AI) is a promising tool to improve prostate lesion detection, lesion
characterization, and lesion volume quantification. AI can systematically evaluate mpMRI images [38].
Machine learning (ML), a branch of AI, and its sub-discipline, deep learning (DL), have become
attractive techniques in medical imaging because of their ability to interpret large amounts of data [39].
By applying ML to prostate mpMRI data, imaging-based clinical decisions could be improved.
The purpose of this review is to summarize ML applications for prostate mpMRI in regards to
(1) prostate organ segmentation, (2) prostate lesion detection and segmentation, and (3) prostate
lesion characterization.
2. Multiparametric Magnetic Resonance Imaging
Multiparametric magnetic resonance imaging (mpMRI) of the prostate is a form of advanced
non-invasive imaging that combines standard anatomical sequences with functional imaging.
It consists of T1-weighted images, T2-weighted images (T2W), and the following functional sequences:
diffusion-weighted images (DWI) including the apparent diffusion coefficient maps (ADC) and dynamic
contrast-enhanced images (DCE). Certain protocols also incorporate proton magnetic resonance
spectroscopy imaging (MRSI) [40,41]. Typically, the functional techniques used are DWI and DCE.
MRSI is more demanding than DWI and DCE because it requires more acquisition time, greater
technical expertise, and intensive post-processing of the data. Therefore, it is not commonly used [42].
The advantages of seeing both the anatomy and functional ability of the prostate have made
mpMRI an attractive imaging technique with many applications. It can accurately identify clinically
relevant cancer. The combination of T2W, DWI, and DCE has high specificity, sensitivity, and negative
predictive value in detecting PCa [43–45]. The use of all three functional sequences has been found to
have a positive predictive value for PCa of 98% [46]. In addition to diagnosing PCa, mpMRI is also
used in the management of the disease as the functional sequences aid in predicting tumor behavior.
Prostate mpMRI has been used for active surveillance, tumor localization, staging, treatment planning,
and monitoring of recurrence [40,41].
While mpMRI is a powerful imaging modality, it does have limitations. Differences in image
acquisition techniques and protocols across institutions lead to heterogeneity in imaging quality and
make it challenging to compare images [47]. Additionally, the learning curve for reading mpMRIs
is steep, and there exists inter-observer variability [48–50]. The experience of radiologists reading
these scans impacts the utility of prostate mpMRI images. In addition, the prostate gland is difficult
to delineate, and various benign and pre-malignant processes can mimic PCa [51]. For example,
the sensitivity for the detection of PCa in the transitional zone is limited by the heterogeneous nature
of this zone in the setting of BPH, which can also exhibit increased cellularity further complicating
the distinction. Furthermore, patient-related factors, including body habitus, prior procedures,
and unconventional anatomy, can impact imaging. Artifacts, such as field inhomogeneity from rectal
gas and metal implants, can substantially impede the interpretation and reporting of prostate mpMRI.
Finally, it can be difficult to discriminate between post-treatment changes and local recurrence following
treatment on mpMRI.
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a plane, car, or boat. In regression, ML receives data and then predicts a numerical value for each item
in the data. Examples include predicting tomorrow’s ambient temperature or the price of a stock.
Within the ML discipline, DL has garnered significant attention because of the groundbreaking
results that it achieved in the ImageNet Large Scale Visual Recognition Challenge competition, where
competitors developed algorithms using a subset of a public dataset of images [58]. DL has flourished
with the rise of big data and faster hardware [39]. In traditional ML, the algorithm has features that it
will extract from the data before training begins [57] (Figure 2). These features are constant and are
based upon established rules. For example, the algorithm can look for eyes when trying to recognize
a face or search for wings when identifying an airplane. By contrast, a DL algorithm does not require
feature selection before training. DL simply receives input and learns its salient features during training
(Figure 2). DL architecture is also notable because it is formed by many tiered layers, which resemble
a brain’s neuronal network. These layers enable DL to extract features from progressively smaller sizes
of input data and allow for increased feature complexity [59]. Although various DL architectures exist,
convolutional neural networks (CNN) are considered well suited for medical imaging. The overall
goal of these techniques is to allow the machine to determine and optimize features automatically for
Cancersand
2020,classifying
12, x
6 of 19
evaluating
images.

Figure 2. Machine learning versus deep learning used for multiparametric magnetic resonance imaging
Figure 2. Machine learning versus deep learning used for multiparametric magnetic resonance
(mpMRI) sequence identification. In machine learning, the computer receives inputs of mpMRI
imaging (mpMRI) sequence identification. In machine learning, the computer receives inputs of
images and goes through feature extraction specific to the different sequences of T2-weighted (T2W),
mpMRI images and goes through feature extraction specific to the different sequences of T2diffusion-weighted imaging (DWI), and dynamic contrast-enhanced (DCE). Then, the computer is
weighted (T2W), diffusion-weighted imaging (DWI), and dynamic contrast-enhanced (DCE). Then,
trained on additional images and is able to identify the correct sequence as an output. Deep learning
the computer is trained on additional images and is able to identify the correct sequence as an
differs from machine learning in that feature extraction and training can be done simultaneously to
output. Deep learning differs from machine learning in that feature extraction and training can be
produce the output.
done simultaneously to produce the output.

Medical imaging studies that use ML algorithms are frequently designed with three dataset
Medical imaging studies that use ML algorithms are frequently designed with three dataset
types: training, validation, and test [60]. The study will first use training data as its input to develop
types: training, validation, and test [60]. The study will first use training data as its input to develop
an algorithm that produces the desired output. During this training period, the algorithm
constantly uses validation data to provide correct feedback to modify itself. After the algorithm has
finished development, final performance is then assessed with test data. Because test data was not
used during the algorithm training, it is an objective method to assess performance.
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Figure 3. Prostate organ segmentation performed by machine learning methods. The computer
multiparametric magnetic resonance imaging images as inputs and applies the developed machine
takes multiparametric magnetic resonance imaging images as inputs and applies the developed
learning algorithm to correctly identify the borders of the prostate.
machine learning algorithm to correctly identify the borders of the prostate.
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with dataset sizes between 81 and 163 patients. The high Dice scores across multiple studies with
comparable network architectures demonstrate substantial progress towards completely automated
prostate segmentation and volume approximation. Table 1 lists the previously discussed studies
along with several others that also segmented the prostate using various CNNs. To establish the
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with dataset sizes between 81 and 163 patients. The high Dice scores across multiple studies with
comparable network architectures demonstrate substantial progress towards completely automated
prostate segmentation and volume approximation. Table 1 lists the previously discussed studies along
with several others that also segmented the prostate using various CNNs. To establish the ground
truth label, which is used in establishing a Dice score, five studies used radiologists, two studies used
clinicians of unstated specialties, one study used an expert, and one study used a radiologist for most
of its data and an unnamed source for the rest of its data [67,70,71,73–78].
Table 1. Machine learning techniques applied to prostate organ segmentation.
Reference

Year

Rundo et al. [67]

2017

Tian et al. [71]
Karimi et al. [70]
Clark et al. [73]
Zhu, Y. et al. [74]
Zhu, Q. et al. [75]
Milletari et al. [76]
Wang, B. et al. [77]

2018
2018
2017
2018
2017
2016
2019

Cheng et al. [78]

2016

ML Algorithm

Patients

Dice

Modalities

Fuzzy C-means clustering.
Features: T1 intensity, T2 intensity
CNN: 7 layers
CNN: 3 layers
CNN: U-Net
CNN: U-Net
CNN: U-Net
CNN: V-Net
CNN: 3D DSD-FCN
CNN and Active
Appearance Model

21

0.91

T1W, T2W

140
49
134
163
81
80
40

0.85
0.88
0.89
0.93
0.89
0.87
0.86

T2W
T2W
DWI
DWI, T2W
T2W
T2W
T2W

120

0.93

T2W

5. Prostate Lesion: Detection, Segmentation, and Volume Estimation
Although prostate lesion detection, segmentation, and volume approximation could benefit PCa
management, an effective tool that can automate these processes has not been created. For prostate lesion
detection, satellite small lesions can be challenging to detect [19]. In a study by Steenbergen et al. [19],
six different teams, each composed of one radiologist and one radiation oncologist, missed 66
out of 69 satellite lesions distributed across 20 patients. In addition to prostate lesion detection,
segmentation is difficult because sparse tumors composed of benign glands and stroma are challenging
to outline [79]. When segmentation across multiple institutions is compared, the contours reveal
considerable differences [80]. As a result of inexact segmentation, volume approximation of prostate
lesions is also challenging and often underestimates the histopathological volume [79]. This need for
improved lesion metrics could be satisfied using ML algorithms that could learn to identify these
features within mpMRI images.
For prostate lesion detection, ML approaches have been used to identify potential malignancies
(Figure 4). Lay et al. [81] used a prostate computer-aided diagnosis (CAD) based on a random forest for
prostate lesion detection (Table 2). This study’s dataset used 224 patient cases across three sequences
(T2-weighted, ADC, and DWI) for a total of 287 benign lesions and 123 lesions with a Gleason score of
6 or higher [81]. The Gleason scoring system describes PCa grades on a scale of 1 to 5 based on the
pattern that the cancerous cells fall into, with 1 or 2 being low grade and 5 being high grade. It uses
the combined grades of the most prominent and second most prominent patterns in a biopsy as the
final score. A Gleason score of 6 or greater has malignant potential [82]. Lay et al.’s random forest
technique yielded an area under the curve (AUC) score of 0.93 [81]; AUC is a measurement for binary
classification and ranges from 0 to 1. Therefore, this study demonstrates that the ML model can detect
lesions with high accuracy.
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Table 2. Machine learning techniques applied to prostate lesion detection.
Reference
Reference
Lay et al. [81]

Lay et al. [81]
Sumathipala et al. [83]

Year
Year
2017

2017
2018

Xu et al. [84]
Sumathipala
et al.
[83]

2018

Xu et al. [84]
Tsehay et al. [85]

2019
2017

Tsehay et al. [85]

2019

2017

ML Algorithm Patients
Patients
Lesions
Modalities
ML Algorithm
Lesions
AUC AUC Modalities
T2W, ADC,
Random Forest.
Forest. Features:
Random
224
410
0.93
DWI
Intensity, Haralick texture
Features:
Intensity,
224
N/A
0.93
T2W, ADC,
DWI
CNN: Holistically Nested
T2W, ADC,
186
N/A
0.93
Haralick
texture
Edge Detection
DWI
CNN: Holistically
T2W, ADC,
CNN: ResNet
346
N/A
0.97
DWI
Nested Edge
186
N/A
0.93
T2W, ADC,
DWI
T2W, ADC,
Detection
CNN, 5 Layers
52
125
0.90
DWI
CNN: ResNet
346
N/A
0.97
T2W, ADC, DWI
CNN, 5 Layers
52
125
0.90
T2W, ADC, DWI

DL techniques
have also been applied to prostate lesion detection (Table 2). Xu et al. [84]
DL techniques have also been applied to prostate lesion detection (Table 2). Xu et al. [84]
implemented
a type
neural
network
with with
extensive
layers,
ResNet
[86],[86],
to find
on T2-weighted,
implemented
a of
type
of neural
network
extensive
layers,
ResNet
to lesions
find lesions
on T2ADC,weighted,
and DWIADC,
images.
This
study
used
images
from
the
Cancer
Imaging
Archive
data
portal
and DWI images. This study used images from the Cancer Imaging Archive
data and
included
346
patients.
achievedThey
an AUC
of 0.97
[84]. of
Tsehay
et al.
[85] also
DLused
algorithm
portal
and
includedThey
346 patients.
achieved
an AUC
0.97 [84].
Tsehay
et al.used
[85] a
also
a
algorithm
with
a 5-layer CNN
that used an
for each
layer. was
with DL
a 5-layer
CNN
architecture
thatarchitecture
used an individual
lossindividual
functionloss
for function
each layer.
The CNN
Theand
CNN
was trained
validated
a dataset
of 39 and
benign
86 alesions
with
trained
validated
on aand
dataset
of 39onbenign
lesions
86 lesions
lesionsand
with
Gleason
6 aorGleason
higher [85].
6
or
higher
[85].
Tsehay’s
group
achieved
an
impressive
AUC
of
0.90
[85],
which
demonstrates
Tsehay’s group achieved an impressive AUC of 0.90 [85], which demonstrates high accuracy ofhigh
prostate
of prostate lesion detection. All four studies in Table 2 used radiologists for labeling the
lesionaccuracy
detection.
All four studies in Table 2 used radiologists for labeling the ground truth [81,83–85].
ground truth [81,83–85].
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with
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U-NetDL
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and Mask R-CNN, respectively. Kohl’s group used a dataset of 152 patients and implemented UKohl’s group used a dataset of 152 patients and implemented U-Net combined with an adversarial
Net combined with an adversarial network. Their architecture resulted in an average Dice score for
network. Their architecture resulted in an average Dice score for prostate lesion segmentation of
prostate lesion segmentation of 0.41 [88]. Dai’s group used a highly specialized DL algorithm, Mask
0.41 [88].
Dai’s
group with
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highly to
specialized
DL algorithm,
Mask
and
R-CNN,
and trained
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lesion Dice
score R-CNN,
of 0.46 [89].
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label the with
63 patients
achieve
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Dice score
of 0.46
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the ground
truth,
Dai
al. [89]
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Kohl
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Table 3. Machine learning techniques applied to prostate lesion segmentation.
Reference
YearYear
ML ML
Algorithm
Patients
Reference
Algorithm
Patients
et al.
[89] 20192019 CNN:
CNN:
Mask
R-CNN
DaiDai
et al.
[89]
Mask
R-CNN
63 63
Adversarial
Network
Adversarial
Network
Kohl
et al.
[88] 20172017
Kohl
et al.
[88]
152152
CNN:
U-Net
and and
CNN:
U-Net
Fuzzy
FuzzyMarkov
MarkovRandom
et al.
[87] 20092009
LiuLiu
et al.
[87]
11 11
RandomFields
Fields

Dice
Dice
0.46
0.46

Modalities
Modalities
T2W, ADC
ADC
T2W,

0.41
0.41

T2W, ADC,
ADC, DWI
T2W,

0.62
0.62

T2W, quantitative
quantitative T2,
T2W,
T2,
DWI,
DWI, DCE

6. Prostate
Lesion:Characterization
Characterization
6. Prostate
Lesion:
Although prostate lesions have been increasingly imaged with mpMRI since 2013 [4], their
Although prostate lesions have been increasingly imaged with mpMRI since 2013 [4], their
characterization has been hindered by the variability in classification conventions across different
characterization has been hindered by the variability in classification conventions across different
radiologists and institutions [4,47,90]. To establish better standardization, the PI-RADS scoring
radiologists and institutions [4,47,90]. To establish better standardization, the PI-RADS scoring system
system was created in 2012, with an updated version PI-RADS v2 released in 2015, and the newest
was created in 2012, with an updated version PI-RADS v2 released in 2015, and the newest version
version PI-RADS v2.1 released in 2019 [53,54,91]. Since their conception, multiple studies have
PI-RADS
v2.1 released in 2019 [53,54,91]. Since their conception, multiple studies have attempted to
attempted to elucidate the clinical utility of PI-RADS, PI-RADS v2, and PI-RADS v2.1. Challenges to
elucidate
the clinical
utility
of PI-RADS,
PI-RADS
v2, and
PI-RADSexperience,
v2.1. Challenges
its broader
its broader
acceptance
include
inter-reader
agreement,
radiologist
and theto
substantial
acceptance
include
inter-reader
agreement,
experience,
andlesion
the substantial
interpretation
interpretation
time
of images [4,47,90].
Thisradiologist
need for more
consistent
characterization
makes
time
of
images
[4,47,90].
This
need
for
more
consistent
lesion
characterization
makes
ML
an attractive
ML an attractive method for accurate, quick classification.
methodML
for algorithms
accurate, quick
classification.
can augment
the PI-RADS scoring system as well as independently classify
ML algorithms
can augment
the PI-RADS
scoring
independently
classify
lesions
(Table 4). Regarding
PI-RADS,
Litjens et
al. [92]system
createdasawell
CADassystem
that applied
a
lesions
(Table
4). Regarding
PI-RADS,
Litjenslesions
et al. [92]
systemfor
that
applied a random
random
forest
for characterizing
prostate
on created
a scale aofCAD
suspicion
malignancy.
After
forest
for characterizing
prostate
lesions
scale of suspicion
malignancy.
combining
combining
the ML generated
scores
andon
thea radiologist
providedfor
PI-RADS
scores After
on a dataset
of
thescores
overalland
AUC
greater than
eitherPI-RADS
the ML generated
or of
the107
PI-RADS
the130
MLpatients,
generated
thewas
radiologist
provided
scores on ascores
dataset
patients,
[92].
Similarly,
Wang,
J. eteither
al. [93],
54 patients
their
also
concluded
that a
thescores
overall
AUC
was greater
than
thewho
MLused
generated
scoresinor
the dataset,
PI-RADS
scores
[92]. Similarly,
support
vector
machine
(SVM)
algorithm
enhanced
the
PI-RADS
performance
of
radiologists.
Song
Wang, J. et al. [93], who used 54 patients in their dataset, also concluded that a support vector machine
et
al.
[94]
opted
to
use
a
DL
algorithm
based
off
of
VGG-Net,
a
deep
CNN,
as
a
tool
for
improving
(SVM) algorithm enhanced the PI-RADS performance of radiologists. Song et al. [94] opted to use a DL
PI-RADSbased
scoresoffassigned
by radiologists.
Song’s
gathered
data PI-RADS
from 195 patients
and alsoby
algorithm
of VGG-Net,
a deep CNN,
as agroup
tool for
improving
scores assigned
observed
that
their
AUC
improved
when
radiologists’
decisions
were
combined
with
the
VGG-Net
radiologists. Song’s group gathered data from 195 patients and also observed that their AUC improved
[94].
when
radiologists’ decisions were combined with the VGG-Net [94].
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Table 4. Machine-learning techniques applied to prostate lesion characterization.
Reference

Year

Algorithm

Patients

Lesions

AUC

Modalities

T2W, DCE, DWI

107

141

Benign vs. Cancer;
AUC increased
from 0.81 to 0.88
with their ML tool
Indolent vs.
Aggressive; AUC
increased from
0.78 to 0.88 with
their ML tool

Litjens et al. [92]

2015

Random Forest.
Features: Intensity,
Position,
Pharmacokinetic,
Texture, Spatial Filter

Wang, J. et al. [93]

2017

SVM. Features:
Volumetric Radiomics

54

149

0.95

T2W, DWI

Song et al. [94]

2018

CNN: Deep CNN and
Augmentation

195

547

0.94

T2W, ADC, DWI

Kwak et al. [95]

2015

SVM. Features:
Texture

244

479

0.89

T2W, DWI

Wang, Z. et al. [96]

2018

CNN: Deep CNN

360

600

0.96

T2W, ADC

Seah et al. [97]

2017

CNN: Deep CNN

346

538

0.84

T2W, ADC, DCE

Liu et al. [98]

2017

CNN: XmasNet

341

538

0.84

T2W, ADC, DWI,
Ktrans

Mehrtash et al.
[99]

2017

CNN: 3D
Implementation

344

538

0.80

ADC, DWI, DCE

2019

Two CNNs: Inception
V3 and VGG-16

Training
Data: 204
Test Data:
N/A

538

Inception V3, 0.81
VGG-16, 0.83

T2W, DWI, DCE

Chen et al. [100]

In addition to bolstering lesion classification by radiologists, ML algorithms have been trained to
characterize prostate lesions independently (Figure 6, Table 4). Many studies explored this task with the
PROSTATEx challenge dataset that was released in 2017 [101]. The PROSTATEx dataset was gathered
from 344 patients and contained segmented lesions along with their respective pathology-defined
Gleason scores [101]. From this public database, Wang, Z. et al. [96] achieved an AUC of 0.96 by
running two CNNs in parallel. Both Seah et al. [97] and Liu et al. [98] obtained an AUC of 0.84 by using
deep layered CNNs. Mehrtash et al. [99] implemented a 3D CNN to reach an AUC of 0.80. One study
by Kwak et al. [95] used its own proprietary dataset to implement an SVM that trained on T2-weighted
and DWI images to characterize prostate lesions. In this study, 244 patients were used for a total of 333
benign and 146 malignant lesions [95]. The SVM method used discriminative features in training that
resulted in an AUC score of 0.89 [95]. All of the studies listed in Table 4 used radiologists to determine
their ground truth [77,92–95,97–100]. These studies highlight the ability of DL algorithms to predict
the likelihood
Cancers 2020, of
12, xa lesion’s malignancy based upon Gleason scores.
12 of 19
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7. Future Work
The potential applications of ML to PCa surpass volume estimation, lesion detection, and
lesion characterization. Further developments in prostate lesion classification may lead to a more
practical clinical use, include training ML algorithms for tumor grade prediction. In addition to
analyzing data solely from images, ML could augment the clinical management of PCa by
incorporating demographic and biochemical data. ML could enable clinicians to make more assured
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7. Future Work
The potential applications of ML to PCa surpass volume estimation, lesion detection, and lesion
characterization. Further developments in prostate lesion classification may lead to a more practical
clinical use, include training ML algorithms for tumor grade prediction. In addition to analyzing
data solely from images, ML could augment the clinical management of PCa by incorporating
demographic and biochemical data. ML could enable clinicians to make more assured decisions
regarding the need for biopsy, medication dosing, and cancer recurrence. Biopsies that are performed
for diagnosing PCa could be rendered unnecessary with a ML tool. Two studies by Hu et al. [102]
and Chen et al. [103] used data such as age, digital rectal exam findings, PSA, and prostate volume
for biopsy prediction. These studies made accurate PCa diagnoses and showed the potential for
ML to eliminate the need for biopsy. In addition to diagnosis, ML could impact PCa medication
dosing in PCa management. Radiation therapy requires accurate dosing, which is frequently operator
dependent [104]. By minimizing operator dependency, ML could offer better standardization leading
to more precise dosing. Nicola et al. [105] employed ML to predict prostate brachytherapy dosing
by analyzing images and prior treatment plans from other patients. This study showed that ML
implementation was comparable to brachytherapists and could be advanced by using a DL instead of
a traditional ML algorithm. Along with diagnosis and dosing, ML could be used for predicting cancer
recurrence after prostatectomy. Two studies by Wong et al. [106] and Cordon et al. [107] gathered data
such as Gleason score, PSA, seminal vesical invasion, and surgical margins to predict recurrence after
prostatectomy. The accuracy of these studies could be increased by adding postoperative imaging data
for improved recurrence prediction.
8. Conclusions
AI applications in prostate mpMRI are promising tools for more effective and efficient image
interpretation, leading to improved care. In pure image interpretation, ML has shown noteworthy
progress in prostate organ segmentation and volume estimation. As better-curated data becomes
available for prostate lesions, ML will likely become more successful at lesion detection, volume
estimation, and characterization. As ML evolves, it will indisputably change radiologists’ workflow by
performing many of the simple tasks in image interpretation. However, ML will not replace the role of
radiologists, who are critical to solving complex clinical problems [104]. AI is poised to enhance the
decisions made by radiologists. It will enable radiologists to better care for their patients rather than
supersede the need for radiologists.
Similarly, ML’s ability to evaluate complex datasets across different domains suggests this
technique may facilitate the bridging of advanced imaging, such as mpMRI, with emerging biomarker
analysis or tumor genetics. Thus, ML may form the underpinnings of radiogenomics, allowing for the
integration of imaging data, blood chemistry analysis, and pathologic evaluation in forming complex
models that can predict treatment response. Enabled by larger datasets and more sophisticated
mathematical techniques, ML could progress to creating completely automated tools that receive
a patient’s prostate mpMRI images and then delineate a range of desired features, as well as giving
likelihood metrics for an array of pathologies.
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